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Background
Monoclonal antibody (mAb) therapy-has changed the nat-
ural history of patients with B cell lymphomas, breast can-
cer, and head and neck cancers. However, response rates
are suboptimal, highlighting the need to enhance mAb
activity. Combining a tumor targeting mAb with a second
antibody that activates natural killer (NK) cells may
improve the therapeutic effects of mAbs. Engagement of
the Fc receptor (FcR) on NK cells by mAbs coating tumor
cells has been previously shown to enhance their expres-
sion of CD137 [1-3]. We conducted preliminary analyses
as a first step toward developing a nomogram to predict
CD137 up-regulation following therapy with mAb.
Methods
Patient tumor and immune characteristics were collected
from patients with Non-Hodgkin’s lymphoma, breast can-
cer, and head and neck cancers receiving mAb therapy as
part of clinical trials. CD137 expression pre- and post-
mAb therapy was assessed by mass cytometry time of
flight (CyTOF) analysis. We examined the difference
(post-pre mAB therapy) in CD137 expression for each
cancer type. Specifically, we applied multivariate lasso
regression tools and used classification and regression
trees (CART) to predict post-CD137 expression, separately
for each cancer type.
Results
We analyzed data from 62 patients with breast cancer,
46 with head/neck cancer and 91 with Non-Hodgkin’s
lymphoma. The difference (post-pre) in CD137 expres-
sion values was significantly different for each cancer
type (mean (SD): Breast: 6.6 (6.5); Head/Neck: 11.0
(7.0); NHL: 7.5 (7.1), p
Conclusions
Our preliminary results suggest that FcR polymorphism,
pre-treatment expression levels of CD137 and age are
significant predictors of CD137 uptake in patients.
Further work validating our models will provide the
opportunity to develop a nomogram that may be used
to individualize this therapeutic approach for patients.
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